Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) have received an average recommendation of “Hold” from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $23.73.

Several brokerages have recently weighed in on AMPH. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, January 24th. Needham & Company LLC downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating and set a $22.20 price target on the stock. in a research note on Wednesday, March 13th. TheStreet downgraded shares of Amphastar Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Monday, March 18th. BidaskClub raised shares of Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, March 3rd. Finally, Piper Jaffray Companies downgraded shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $24.00 to $23.00 in a research note on Wednesday, March 13th.

Shares of AMPH traded down $0.07 during midday trading on Monday, hitting $20.65. The stock had a trading volume of 1,949 shares, compared to its average volume of 205,472. Amphastar Pharmaceuticals has a 1 year low of $14.40 and a 1 year high of $25.43. The company has a market cap of $969.49 million, a P/E ratio of 98.33, a P/E/G ratio of 2.40 and a beta of 1.37. The company has a current ratio of 2.06, a quick ratio of 1.41 and a debt-to-equity ratio of 0.09.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Tuesday, March 12th. The company reported $0.13 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.02. Amphastar Pharmaceuticals had a negative net margin of 1.96% and a positive return on equity of 3.17%. The business had revenue of $89.69 million for the quarter, compared to the consensus estimate of $75.46 million. Analysts predict that Amphastar Pharmaceuticals will post 0.35 earnings per share for the current fiscal year.

In related news, SVP Yakob Liawatidewi sold 3,183 shares of the firm’s stock in a transaction dated Wednesday, January 16th. The shares were sold at an average price of $22.15, for a total value of $70,503.45. Following the transaction, the senior vice president now owns 37,471 shares of the company’s stock, valued at approximately $829,982.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jason B. Shandell sold 32,336 shares of the firm’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $20.35, for a total transaction of $658,037.60. Following the transaction, the insider now directly owns 160,490 shares in the company, valued at approximately $3,265,971.50. The disclosure for this sale can be found here. Insiders sold a total of 116,305 shares of company stock worth $2,632,315 in the last ninety days. 31.50% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Tibra Equities Europe Ltd purchased a new position in shares of Amphastar Pharmaceuticals during the 1st quarter valued at approximately $644,000. Geode Capital Management LLC increased its holdings in shares of Amphastar Pharmaceuticals by 9.5% during the 4th quarter. Geode Capital Management LLC now owns 425,301 shares of the company’s stock valued at $8,462,000 after purchasing an additional 36,784 shares in the last quarter. Nordea Investment Management AB increased its holdings in shares of Amphastar Pharmaceuticals by 4.4% during the 4th quarter. Nordea Investment Management AB now owns 249,728 shares of the company’s stock valued at $4,970,000 after purchasing an additional 10,569 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in shares of Amphastar Pharmaceuticals during the 4th quarter valued at approximately $235,000. Finally, Millennium Management LLC increased its holdings in shares of Amphastar Pharmaceuticals by 66.3% during the 4th quarter. Millennium Management LLC now owns 140,507 shares of the company’s stock valued at $2,796,000 after purchasing an additional 56,001 shares in the last quarter. 47.51% of the stock is currently owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Featured Story: How to find the components of the quick ratio

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.